Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Conditions: Synovial Sarcoma Interventions: Drug: Fludarabine phosphate; Drug: NY-ESO-1 TCR/IL-15 NK; Drug: Cyclophosphamide Sponsors: M.D. Anderson Cancer Center Not yet recruiting

https://clinicaltrials.gov/study/NCT06083883

Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials